CAR-T 细胞疗法计划

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

2. A Study to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

   Rochester, Minn.

   This study aims to evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction (STAD) or pancreatic adenocarcinoma (PAAD) and identify the maximum tolerated dose (MTD) and a recommended Phase 2 dose (RP2D) of CT041 therapy.

3. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

   Rochester, Minn.

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome.

4. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the safety of nonconforming lisocabtagene maraleucel in patients, and to assess the effectiveness of nonconforming lisocabtagene maraleucel in patients.

5. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the effectiveness and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1) and in subjects with HR MM having progressed within one year of initial treatment (Cohort 2). Approximately 122 subjects will be enrolled into one of two cohorts. Cohort 1 will enroll approximately 73 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2 will enroll approximately 49 MM subjects with 1 prior anti-myeloma treatment regimen and HR disease defined as Stage III by the Revised International Staging System (R-ISS) and early relapse. The cohorts will start in parallel and independently.

6. AUTO1 in Relapsed or Refractory B-ALL

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and effectiveness of AUTO1 (t-cells) in adult patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (r/r B-ALL).

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

2. A Study to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

   Rochester, Minn.

   This study aims to evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction (STAD) or pancreatic adenocarcinoma (PAAD) and identify the maximum tolerated dose (MTD) and a recommended Phase 2 dose (RP2D) of CT041 therapy.

3. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

   Rochester, Minn.

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome.

4. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the safety of nonconforming lisocabtagene maraleucel in patients, and to assess the effectiveness of nonconforming lisocabtagene maraleucel in patients.

5. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the effectiveness and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1) and in subjects with HR MM having progressed within one year of initial treatment (Cohort 2). Approximately 122 subjects will be enrolled into one of two cohorts. Cohort 1 will enroll approximately 73 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2 will enroll approximately 49 MM subjects with 1 prior anti-myeloma treatment regimen and HR disease defined as Stage III by the Revised International Staging System (R-ISS) and early relapse. The cohorts will start in parallel and independently.

6. AUTO1 in Relapsed or Refractory B-ALL

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and effectiveness of AUTO1 (t-cells) in adult patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (r/r B-ALL).